Track topics on Twitter Track topics that are important to you
Quest Diagnostics has introduced three new cancer test services, which will enable clinicians to predict the development of hereditary forms of cancer in individuals.
Cancer diagnostics market is witnessing high growth due to increasing prevalence and incidences of several types of cancers. The post Cancer diagnostics market is witnessing high growth appeared firs...
Personal Genome Diagnostics (PGDx), a leading provider of advanced cancer genome testing products and services, has announced its participation in the Blood Profiling Atlas pilot of the Cancer Moonsho...
Breast Cancer Index & CancerTYPE ID Tests Provide Patient-Specific Information to Aid in Treatment Decisions with the Goal of Improving Outcomes SAN DIEGO & PALO ALTO, Calif.–(BUSINESS W...
AccuraGen Holdings, a US-China cancer diagnostics company, has closed a $40 million Series B financing. AccuraGen develops blood tests that sequence cell free DNA (cfDNA) to provide sensitive and accu...
Thursday, September 22nd 2016 at 5:18pm UTC Breast Cancer Index & CancerTYPE ID Tests Provide Patient-Specific Information to Aid in Treatment Decisions with the Goal of Improving Outcomes SAN DIE...
Cernostics, a Pittsburgh, PA-based cancer diagnostics startup has raised $5 million in funding led by UPMC Enterprises, UPMC’s venture capital arm with participation from Novitas Capital. The co...
IBM Watson Health and Quest Diagnostics have introduces new service, which will enable physicians to provide precision cancer treatments for patients across the US.
The importance of RAS mutation in carcinogenesis is established, and knowledge of an individual cancer's mutation status is important for optimal treatment.
Single-cell proteomics in cancer is evolving and promises to provide more accurate diagnoses based on detailed molecular features of cells within tumors. This review focuses on technologies that allow...
Companion diagnostics (CDx) have become a major tool in molecular pathology and assist in therapy decisions in an increasing number of various cancers. Particularly, the developments in lung cancer ha...
This commentary highlights the article by Misyura et al that underscores the use of next-generation sequencing platforms for detection and verification of somatic variants.
The RNA-seq approach for prostate cancer candidate RNA biomarkers screening in plasma and urine obtained by minimally invasive or noninvasive methods is proved to be feasible. Significant amount of RN...